BACKGROUND AND PURPOSE: To investigate the effect of short-term high-dose atorvastatin on blood and plaque inflammation in patients with carotid stenosis. METHODS:Twenty patients undergoing carotid endarterectomy without previous statin treatment were randomized to receive either atorvastatin 80 mg/d (n=11) or no statins (n=9) for 1 month. We studied inflammatory mediators in plasma (enzyme-linked immunosorbent assay), peripheral blood mononuclear cells (PBMCs; quantitative RT-PCR and EMSA) and plaques (immunohistochemistry and Southwestern histochemistry). RESULTS:Atorvastatin significantly decreased total and low-density lipoprotein cholesterol and prostaglandin E2 plasma levels. PBMCs from treated patients showed impaired NF-kappaB activation and MCP-1 and COX-2 mRNA expression. Carotid atherosclerotic plaques demonstrated a significant reduction in macrophage infiltration, activated NF-kappaB, and COX-2 and MCP-1 expression. CONCLUSIONS: Intensive treatment with atorvastatin decreases inflammatory activity of PBMCs and carotid atherosclerotic plaques in 1 month. These data strongly suggest that the antiinflammatory effect of high doses of statins in humans can be seen very early.
RCT Entities:
BACKGROUND AND PURPOSE: To investigate the effect of short-term high-dose atorvastatin on blood and plaque inflammation in patients with carotid stenosis. METHODS: Twenty patients undergoing carotid endarterectomy without previous statin treatment were randomized to receive either atorvastatin 80 mg/d (n=11) or no statins (n=9) for 1 month. We studied inflammatory mediators in plasma (enzyme-linked immunosorbent assay), peripheral blood mononuclear cells (PBMCs; quantitative RT-PCR and EMSA) and plaques (immunohistochemistry and Southwestern histochemistry). RESULTS:Atorvastatin significantly decreased total and low-density lipoprotein cholesterol and prostaglandin E2 plasma levels. PBMCs from treated patients showed impaired NF-kappaB activation and MCP-1 and COX-2 mRNA expression. Carotid atherosclerotic plaques demonstrated a significant reduction in macrophage infiltration, activated NF-kappaB, and COX-2 and MCP-1 expression. CONCLUSIONS: Intensive treatment with atorvastatin decreases inflammatory activity of PBMCs and carotid atherosclerotic plaques in 1 month. These data strongly suggest that the antiinflammatory effect of high doses of statins in humans can be seen very early.
Authors: Gabriel A Bonaterra; Wulf Hildebrandt; Anne Bodens; Roland Sauer; Klaus A Dugi; Hans-Peter Deigner; Dan Turcanu; Helmut Heinle; Wulf Dröge; Jürgen Metz; Ralf Kinscherf Journal: J Mol Med (Berl) Date: 2006-10-17 Impact factor: 4.599
Authors: José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck Journal: Cardiovasc Res Date: 2019-01-01 Impact factor: 10.787
Authors: Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega Journal: Antioxid Redox Signal Date: 2015-01-01 Impact factor: 8.401
Authors: Andreia A Canalli; Renata F Proença; Carla F Franco-Penteado; Fabiola Traina; Tatiana M Sakamoto; Sara T O Saad; Nicola Conran; Fernando F Costa Journal: Haematologica Date: 2010-12-20 Impact factor: 9.941
Authors: G Herrero-Beaumont; M E Marcos; O Sánchez-Pernaute; R Granados; L Ortega; E Montell; J Vergés; J Egido; R Largo Journal: Br J Pharmacol Date: 2008-04-21 Impact factor: 8.739
Authors: Masood A Khan; Richard M Gallo; Gourapura J Renukaradhya; Wenjun Du; Jacquelyn Gervay-Hague; Randy R Brutkiewicz Journal: J Immunol Date: 2009-04-15 Impact factor: 5.422